Standard

T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. / Heijink, D. M.; Kater, A. P.; Hazenberg, M. D. et al.

In: Netherlands journal of medicine, Vol. 74, No. 4, 2016, p. 147-151.

Research output: Contribution to journal › Review article › Academic › peer-review

Harvard

Heijink, DM, Kater, AP, Hazenberg, MD, Hagenbeek, A & Kersten, MJ 2016, 'T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy', Netherlands journal of medicine, vol. 74, no. 4, pp. 147-151.

APA

Heijink, D. M., Kater, A. P., Hazenberg, M. D., Hagenbeek, A., & Kersten, M. J. (2016). T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. Netherlands journal of medicine, 74(4), 147-151.

Vancouver

Heijink DM, Kater AP, Hazenberg MD, Hagenbeek A, Kersten MJ. T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. Netherlands journal of medicine. 2016;74(4):147-151.

Author

Heijink, D. M. ; Kater, A. P. ; Hazenberg, M. D. et al. / T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. In: Netherlands journal of medicine. 2016 ; Vol. 74, No. 4. pp. 147-151.

BibTeX

@article{bc7c3121e21b4e229642fbf40a576947,
title = "T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy",
abstract = "CAR T-cells are autologous T-cells transduced with a chimeric antigen receptor (CAR). The CAR contains an antigen recognition part (originating from an antibody), a T-cell receptor transmembrane and cytoplasmic signalling part, and one or more co-stimulatory domains. While CAR T-cells can be directed against any tumour target, most experience thus far has been obtained with targeting of the B-cell antigen CD19 that is expressed by B-cell acute lymphocytic leukaemia, chronic lymphocytic leukaemia and other B-cell lymphomas. The first clinical results are promising, although there are profound differences in response between patients with different haematological malignancies. Treatment-related side effects have been observed that require specific management. This review will explain the mechanism of action, summarise the experience to date and point out future directions for this hopeful new addition to the therapeutic armamentarium in the treatment of lymphoproliferative B-cell malignancies",
author = "Heijink, {D. M.} and Kater, {A. P.} and Hazenberg, {M. D.} and A. Hagenbeek and Kersten, {M. J.}",
year = "2016",
language = "English",
volume = "74",
pages = "147--151",
journal = "Netherlands journal of medicine",
issn = "0300-2977",
publisher = "Van Zuiden Communications BV",
number = "4",

}

RIS

TY - JOUR

T1 - T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy

AU - Heijink, D. M.

AU - Kater, A. P.

AU - Hazenberg, M. D.

AU - Hagenbeek, A.

AU - Kersten, M. J.

PY - 2016

Y1 - 2016

N2 - CAR T-cells are autologous T-cells transduced with a chimeric antigen receptor (CAR). The CAR contains an antigen recognition part (originating from an antibody), a T-cell receptor transmembrane and cytoplasmic signalling part, and one or more co-stimulatory domains. While CAR T-cells can be directed against any tumour target, most experience thus far has been obtained with targeting of the B-cell antigen CD19 that is expressed by B-cell acute lymphocytic leukaemia, chronic lymphocytic leukaemia and other B-cell lymphomas. The first clinical results are promising, although there are profound differences in response between patients with different haematological malignancies. Treatment-related side effects have been observed that require specific management. This review will explain the mechanism of action, summarise the experience to date and point out future directions for this hopeful new addition to the therapeutic armamentarium in the treatment of lymphoproliferative B-cell malignancies

AB - CAR T-cells are autologous T-cells transduced with a chimeric antigen receptor (CAR). The CAR contains an antigen recognition part (originating from an antibody), a T-cell receptor transmembrane and cytoplasmic signalling part, and one or more co-stimulatory domains. While CAR T-cells can be directed against any tumour target, most experience thus far has been obtained with targeting of the B-cell antigen CD19 that is expressed by B-cell acute lymphocytic leukaemia, chronic lymphocytic leukaemia and other B-cell lymphomas. The first clinical results are promising, although there are profound differences in response between patients with different haematological malignancies. Treatment-related side effects have been observed that require specific management. This review will explain the mechanism of action, summarise the experience to date and point out future directions for this hopeful new addition to the therapeutic armamentarium in the treatment of lymphoproliferative B-cell malignancies

M3 - Review article

C2 - 27185772

VL - 74

SP - 147

EP - 151

JO - Netherlands journal of medicine

JF - Netherlands journal of medicine

SN - 0300-2977

IS - 4

ER -

ID: 2914860